Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells

BACKGROUND: Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Marcia A, Gigliotti, Nicole M, Dotson, Abby L, Rosenwasser, Lanny J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875359/
https://www.ncbi.nlm.nih.gov/pubmed/24004581
http://dx.doi.org/10.1186/2045-7022-3-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875359/
https://www.ncbi.nlm.nih.gov/pubmed/24004581
http://dx.doi.org/10.1186/2045-7022-3-29

Ejemplares similares